Incyte (INCY) shares have shown solid momentum over the past month, gaining 12% and delivering a 21% return over the past 3 months. The company continues to draw investor attention for its performance ...
A month has gone by since the last earnings report for Incyte (INCY). Shares have added about 17.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...
Jefferies analyst Kelly Shi maintained a Buy rating on Incyte today and set a price target of $120.00. Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
We recently published Wall Street Can’t Keep up With These 10 Crushing Stocks; 6 at Fresh Record Highs. Incyte Corp. (NASDAQ:INCY) is one of the best-performing on Monday. Incyte extended its winning ...
Greetings, and welcome to the Incyte Third Quarter 2025 Earnings Conference Call webcast [Operator Instructions]. As a reminder, this conference is being recorded. It's now my pleasure to turn the ...
Incyte Corporation (NASDAQ:INCY) is one of the most profitable biotech stocks to buy. Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Incyte Corporation (NASDAQ:INCY) on ...
Transaction value calculated using the SEC Form 4 weighted average purchase price ($85.85) as of the transaction date (October 3, 2025); Post-transaction value calculated using the SEC Form 4 weighted ...
Hosted on MSN
Wells Fargo Upgrades Incyte (INCY)
Fintel reports that on August 6, 2025, Wells Fargo upgraded their outlook for Incyte (NasdaqGS:INCY) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 6.78% Upside As of August 6, 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback